PharmaFocus Today – Page 4 – media

Xuanjing Biotech Completes Over 200 Million Yuan Pre-A Round Financing

On March 20, Rigerna Therapeutics (Suzhou Xuanjing Biotechnology Co., Ltd.) announced the completion of a Pre‑A financing round totaling over 200 million yuan, led by Kangjun Capital. Participating investors include Delian Capital, Huatai‑GenScript Fund, Jinyi Fuxin, Guohai Innovation Capital, Lenovo Capital, and existing shareholder Yuanxi Haihe Fund, Xuanjing Biological. Founded in 2022, Rigerna Therapeutics is innovation‑driven and focuses on nephrology and metabolic diseases, aiming to become a leader and innovator in the small nucleic acid (oligonucleotide) pharmaceutical field Xuanjing Biological. With forward‑looking strategic planning, its lead pipeline has entered Phase II clinical trials and is poised to become the world’s first approved small nucleic acid drug for IgA nephropathy. Addressing unmet clinical needs in renal and metabolic disorders, Rigerna is developing multiple First‑in‑class programs, building a multi‑layered, gradient pipeline matrix. The completion of this financing round and advancement of several BD collaborations have secured substantial cash reserves, laying a solid ...
- Source: drugdu
- 61
- March 20, 2026
Chia Tai Tianqing’s First Class 1 New Drug TQB6457 Approved for Clinical Trials, World’s First CCR8+PD-1 Fixed-Dose Combination

Recently, TQB6457 Injection, a Class 1 innovative drug developed by Chia Tai Tianqing Pharmaceutical Group, a core subsidiary of China Biologic Products Holdings, Inc. (1177.HK), has been granted clinical trial implied approval by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for the treatment of advanced malignant tumors. As the world’s first fixed-dose combination of a CCR8 monoclonal antibody and a PD‑1 antibody to enter clinical research, this product is designed to replace combination therapy with a single agent, helping to improve medication adherence among patients with advanced tumors and overcome treatment limitations. CCR8 is a promising target specifically and highly expressed on the surface of regulatory T cells (Tregs) in the tumor microenvironment, and plays a key role in recruiting Tregs to tumor sites. PD‑1 is a canonical immune checkpoint protein; tumor cells can trigger immunosuppression by binding PD‑1 via PD‑L1. As a dual-targeted ...
- Source: drugdu
- 65
- March 20, 2026
One Deputy General Manager Resigns, Three Deputies Appointed in Reshuffle Originally produced, Xiaolin, Saibailan, 20

Sinopharm Accord continues senior management reshuffle. 01 Sinopharm Accord Realigns Its Leadership Team On March 17, Sinopharm Accord Co., Ltd. (“Sinopharm Accord”) announced that Wang Chu, Deputy General Manager, had resigned due to work relocation and would not hold any other positions at the company after resignation. Wang Chu was primarily responsible for commercial sales. He assumed the post of Deputy General Manager of Sinopharm Accord in March 2025 and left after only one year in office. He currently remains the legal representative of Sinopharm Holding Guangzhou Co., Ltd., a wholly-owned subsidiary of Sinopharm Accord. This marks the second deputy general manager to depart Sinopharm Accord in the past six months. In November 2025, Chen Changbing, Deputy General Manager in charge of strategic planning, investment and M&A, left ahead of schedule; his original term was set to expire in July 2027. Following Wang Chu’s departure, Sinopharm Accord’s senior management team ...
- Source: drugdu
- 48
- March 20, 2026
Huarun to Part Ways with Hefei Tianmai Biotech at a Valuation of 1.93 Billion Yuan

From an aggressive M&A spree to a now selective asset manager, China Resources Pharmaceutical has begun to shift its logic in selecting and exiting investment targets. 01 Ending a Decade-Long Partnership China Resources Pharmaceutical Continues Asset Divestment On March 16, China Resources Pharmaceutical announced a plan to sell a 5.88% equity stake in Hefei Tianmai Biotech Co., Ltd. (“Tianmai Biotech”) via public listing at a price of 510 million yuan. This marks the second disposal of Tianmai Biotech shares by China Resources Pharmaceutical in just over a month. In February this year, it put a 17.87% stake up for transfer at a reserve price of 1.42 billion yuan. The combined reserve prices of the two transactions total 1.93 billion yuan, and the two deals are independent of each other. Data from Qichacha shows that China Resources Pharmaceutical Investment, a wholly-owned subsidiary of China Resources Pharmaceutical, is the largest shareholder ...
- Source: drugdu
- 72
- March 20, 2026
March 18th National Liver Care Day | Seize the new hope for a cure, don’t let hepatitis B “endure” into liver cancer.

The theme of National Liver Care Day on March 18, 2026, is “Curbing Cirrhosis and Staying Away from Liver Cancer.” For my country, a country with a high prevalence of hepatitis B, this theme is particularly weighty and urgent. The data is alarming: In 2022, my country saw approximately 367,700 new cases of liver cancer and 316,500 deaths, ranking fourth and second among malignant tumors in terms of incidence and mortality, respectively. Even more alarming is that the vast majority of liver cancer patients in my country have a background of hepatitis B virus (HBV) infection, with over 70% of primary liver cancer patients testing positive for hepatitis B surface antigen. Due to late detection, the 5-year overall survival rate for liver cancer patients in my country is less than 15%. However, many hepatitis B patients still have a fatal misconception: ” I have no symptoms and my transaminase levels ...
- Source: drugdu
- 57
- March 19, 2026
A new player enters the race to tap into the $8 billion market! A blockbuster prostate cancer drug welcomes its next challenger.

Recently, the NMPA (National Medical Products Administration) released its latest drug marketing approval announcement, officially approving the marketing of Enzalutamide tablets from Aurite Pharmaceuticals, which is considered to have passed the consistency evaluation. This makes Aurite the third company, following Sichuan Kelun and Qilu Pharmaceutical, to obtain consistency evaluation approval for this product, signifying a further escalation of competition in the market for blockbuster generic prostate cancer drugs. Enzalutamide was originally developed by Astellas and Pfizer, and marketed under the brand name “Xtandi”. As an androgen receptor (AR) inhibitor, enzalutamide plays a crucial role in the treatment of prostate cancer. In August 2012, it was first approved by the US FDA for the treatment of advanced castration-resistant prostate cancer; it officially entered the Chinese market in 2019, becoming an important treatment option for prostate cancer patients in China. From a global market perspective, enzalutamide’s performance has been remarkable. Public data ...
- Source: drugdu
- 60
- March 19, 2026
Shanghai Pharmaceuticals’ cefazolin sodium for injection has passed the generic drug consistency evaluation

On March 18, Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Shangyao Xinya Pharmaceutical Co., Ltd., recently received the “Approval Notice for Supplementary Drug Application” issued by the National Medical Products Administration for its cefazolin sodium for injection, indicating that the drug has passed the consistency evaluation of generic drug quality and efficacy. According to reports, cefazolin sodium for injection is indicated for the treatment of respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infective endocarditis, hepatobiliary system infections, reproductive system infections, and perioperative infection prevention caused by susceptible bacteria. In July 2024, Shanghai Pharmaceuticals New Asia submitted an application to the National Medical Products Administration for consistency evaluation of generic versions of this drug, which was accepted. Shanghai Pharmaceuticals stated that products that pass the consistency evaluation will receive greater support in areas such as medical insurance reimbursement and procurement by medical ...
- Source: drugdu
- 50
- March 19, 2026
HB0025 injection initiates Phase III clinical trial for endometrial cancer

Huahai Pharmaceutical(600521) announced on March 19 that its subsidiary, Shanghai Huaaotai Biotechnology Co., Ltd.Following the completion of the Phase II clinical trial and the pre-initiation meeting for the Phase III clinical trial with the Center for Drug Evaluation of the National Medical Products Administration, the company’s independently developed HB0025 injection will officially commence Phase III clinical trials for advanced/recurrent endometrial cancer. This trial will primarily evaluate the therapeutic efficacy, safety, and tolerability of HB0025 in combination with chemotherapy. To date, the company’s total R&D investment in the HB0025 project is approximately RMB 342 million. According to the announcement, HB0025 is an innovative anti-PD-L1/VEGF bispecific fusion protein that simultaneously targets the tumor immune escape pathway PD-L1 and the tumor angiogenesis pathway VEGF, possessing a dual anti-tumor mechanism of “immune enhancement + anti-angiogenesis”. Currently, there are no completely similar products on the market domestically or internationally. The development of this product will ...
- Source: drugdu
- 56
- March 19, 2026
Industry News | Bowang Pharmaceutical’s siRNA therapy granted Fast Track designation by the FDA

On March 16, Bowang Pharmaceutical announced that its investigational siRNA therapy BW-20805 received Fast Track designation from the U.S. FDA for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disorder that causes sudden, unpredictable swelling in different parts of the body. Severe cases can lead to laryngeal edema, with a mortality rate as high as approximately 40%. BW-20805 is an siRNA therapy targeting prokallikrein (PKK). By targeting PKK mRNA and inhibiting PKK gene expression, it holds promise for providing long-term flare prevention for patients with heart attack (HAE). PKK is currently a well-established therapeutic target in HAE treatment. Recent data presented by Bowang Pharmaceuticals at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting showed that BW-20805 significantly reduces plasma PKK levels and achieves a clinically significant reduction in HAE flare rates. Bowang Pharmaceuticals is currently conducting a Phase 2 clinical trial in adult HAE ...
- Source: drugdu
- 59
- March 19, 2026
Chongqing Yaoyou Pharmaceutical Receives Approval for 2 Billion Yuan Worth of Injectable Drugs

Moxifloxacin hydrochloride sodium chloride injection is an 8-methoxyfluoroquinolone antibiotic with broad-spectrum activity and bactericidal effects. It is suitable for acute bacterial sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia, complicated/uncomplicated skin and skin tissue infections, and complicated intra-abdominal infections caused by susceptible bacteria. According to data from Menet.com , Moxifloxacin Hydrochloride Sodium Chloride Injection is a Class B drug covered by the National Medical Insurance and a National Essential Medicines List. In 2024, its sales in China’s three major terminals and six major markets approached 2 billion yuan, recovering to the level before the implementation of the national centralized procurement policy. However, it experienced a certain degree of decline in the first three quarters of 2025. Sales of Moxifloxacin Hydrochloride Sodium Chloride Injection in China’s Three Major Terminals and Six Major Markets in Recent Years (Unit: RMB 10,000) Source: Menet Pattern Database Currently, more than 30 domestic companies have passed ...
- Source: drugdu
- 40
- March 19, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.